Become a member of BioTechniques (it's free!) and receive the latest news in the life sciences, member-exclusives and 10% off BioTechniques article processing fees

First and PhoreMost: an insight into targeted protein degradation with Neil Torbett

Written by Neil Torbett (PhoreMost)
Conferences Drug discovery and development Interviews Lab design and machinery

Neil Torbett is the CEO of PhoreMost, a biotechnology company based in Cambridge (UK) that is developing a pipeline of novel E3-ligase-based ‘next-generation’ degrader therapeutics. Our Assistant Editor, Beatrice Bowlby, caught up with Neil at BioTrinity 2023 (25–26 April; London, UK) to discuss PhoreMost’s proprietary drug target identification platform, SITESEEKER®. Neil’s background is in cancer research, completing his PhD on protein kinases before working on PI3 kinase during his postdoc and early part of his biotech career. Neil joined PhoreMost 6 years ago as CBO and became CEO in March 2022. Since joining, Neil has overseen the development of PhoreMost’s...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!